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Abstract
Background
Usher syndrome (USH) is a genetically heterogeneous deafness-blindness syn-
drome, divided into three clinical subtypes: USH1, USH2 and USH3.
Methods
Mutations in 21 out of 26 investigated Danish unrelated individuals with USH
were identified, using a combination of molecular diagnostic methods.
Results
Before Next Generation Sequencing (NGS) became available mutations in nine
individuals (1 USH1, 7 USH2, 1 USH3) were identified by Sanger sequencing
of USH1C, USH2A or CLRN1 or by Arrayed Primer EXtension (APEX)
method. Mutations in 12 individuals (7 USH1, 5 USH2) were found by tar-
geted NGS of ten known USH genes. Five novel pathogenic variants were iden-
tified. We combined our data with previously published, and obtained an
overview of the USH mutation spectrum in Denmark, including 100 unrelated
individuals; 32 with USH1, 67 with USH2, and 1 with USH3. Macular edema
was observed in 44 of 117 individuals. Olfactory function was tested in 12 indi-
viduals and found to be within normal range in all.
Conclusion
Mutations that lead to USH1 were predominantly identified in MYO7A (75%),
whereas all mutations in USH2 cases were identified in USH2A. The MYO7A
mutation c.93C>A, p.(Cys31*) accounted for 33% of all USH1 mutations and
the USH2A c.2299delG, p.(Glu767Serfs*21) variant accounted for 45% of all
USH2 mutations in the Danish cohort.
Introduction
Usher syndrome (USH) is an autosomal recessive deafness-
blindness disorder characterized by congenital hearing
impairment, progressive visual loss due to retinitis pigmen-
tosa (RP), and vestibular dysfunction in some cases. The
prevalence has been estimated to be 3.5–16.6 in 100,000
(Boughman et al. 1983; Grondahl and Mjoen 1986;
ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Rosenberg et al. 1997; Kimberling et al. 2010). Based on
clinical findings USH is divided into three subtypes; USH1
(OMIM #276900), USH2 (OMIM #276901) and USH3
(OMIM #276902) differentiated by the degree of hearing
loss, the age of onset of RP and the presence or absence of
vestibular function (Moller et al. 1989; Smith et al. 1994).
USH1 is the most severe form of the three types and is char-
acterized by severe to profound congenital hearing impair-
ment, prepubertal onset of RP, and vestibular dysfunction.
USH2 is defined by congenital moderate to severe hearing
impairment, onset of RP in the first or second decade of
life, and normal vestibular function. USH3 is characterized
by a congenital or early onset of progressive hearing impair-
ment, whereas the onset and severity of RP as well as the
vestibular function are highly variable (Smith et al. 1994;
Hope et al. 1997). Currently, 14 genes associated with USH
have been identified. Six genes involved in USH1 have been
identified: MYO7A (OMIM *276903), USH1C (OMIM
*605242), PCDH15 (OMIM *605514), USH1G (OMIM
*607696), CDH23 (OMIM *605516), and CIB2 (OMIM
*605564). Three genes underlying USH2 have been identi-
fied: USH2A (OMIM *608400), ADGRV1 (OMIM
*602851), and DFNB31 (OMIM *607084). In addition,
CLRN1 (OMIM *606397) has been ascertained in USH3
and both HARS (OMIM *614504) and ABHD12 (OMIM
*613599) in atypical USH (Joensuu et al. 2001; Ness et al.
2003; Eisenberger et al. 2012; Puffenberger et al. 2012).
Finally, two modifier genes, PDZD7 (OMIM *612971) and
CEP250 (OMIM *609689) have been recognized (Eber-
mann et al. 2010; Khateb et al. 2014). The encoded pro-
teins interact in protein complexes in the hair cells of the
inner ear, and in the photoreceptors of the eye (Kremer
et al. 2006; Reiners et al. 2006; El-Amraoui and Petit 2014).
Individuals with USH from Denmark have previously been
investigated for mutations in USH genes. In an early study
individuals with USH1 were investigated for mutations in
MYO7A (Janecke et al. 1999; Dreyer et al. 2000, 2008)
investigated individuals with USH2 for mutations in
USH2A. Mixed groups of USH cases have been investigated
for mutations in several genes using Arrayed Primer EXten-
sion (APEX); Cremers et al. 2007; Tranebjærg et al. 2011.
Recently USH patients were investigated for exon deletions/
duplications in USH2A and PCDH15 by Multiplex ligation-
dependent probe amplification (MLPA); Dad et al. 2015.
This study presents the results of molecular examinations
of 26 individuals with USH residing in Denmark using a
combination of APEX microarray for identification of pre-
viously reported mutations, traditional Sanger sequencing
of single candidate genes, or targeted Next-Generation
Sequencing (NGS) of a panel of 10 genes, associated with
USH.
By combining the mutation data obtained in this study
with all previously published molecular data on USH
patients from Denmark we obtained a overview of the
identified mutations in 100 Danish individuals with USH.
Materials, Subjects and Methods
Ethical compliance
The study was approved by the Regional Research Ethics
Committee (H-3-2011-070) and carried out in accordance
with the Declaration of Helsinki.
Patients
In this study, 26 unrelated individuals with USH residing in
Denmark (cohort 1, Fig. 1) were investigated for mutations.
By combining the mutation data obtained in this study
with all previously published molecular data on 118
patients belonging to 100 families with USH registered at
the Danish National Eye Clinic for the Visually Impaired
at the Kennedy Center (whole cohort), we obtained an
overview of all disease causing mutations hitherto identi-
fied in 100 Danish individuals with USH. Additional 5
patients with no mutations identified are registered. In
addition to the mutations, the gender and some clinical
symptoms of the patients are noted in Tables S1–S3.
Consents to genetic testing were obtained for all
included individuals.
Clinical examinations
All patients were diagnosed at the National Eye Clinic
(Rigshospitalet, Denmark). Based on routine clinical exami-
nations including visual acuity, slit-lamp examination,
fundoscopy, visual field examination, full-field elec-
troretinography (ffERG), and optical coherence tomography
(OCT). Audiological information from different out-patient
clinics was available from 70 patients from the whole cohort
(15 USH1, 54 USH2 and 1 USH3). Vestibular function was
not assessed in this study. A majority of the information
came from practicing otologists who normally do not obtain
vestibular function. Information regarding the onset of
visual and hearing impairment was retrospectively sampled
from the files of the patients. Supplementary information
was received from the patients upon request. Forty-six indi-
viduals (42 families; 13 USH1, 28 USH2 and 1 USH3) com-
pleted a questionnaire including general information about
onset of night blindness, hearing loss and family history.
Despite the missing information on vestibular function our
diagnostic classification had a high precision.
Olfactory function
Olfactory function was tested with the standardized Snif-
fin’ Sticks 12-item test (Burghart, Wedel, Germany). The
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kit includes 12 felt-tip pens, where each pen contains one
common odor (orange, leather, cinnamon, peppermint,
banana, lemon, liquorice, coffee, cloves, pineapple, rose
and fish). The test comprises a forced choice identifica-
tion task, where the individual is presented to each pen
for 30 sec, and is then asked to select the correct odors
from four possible answers. The results generate a score
compared to the age of normalized data presented in a
normogram. According to the manufactures protocol a
score >10 is normal and a score ≤10 suggests that further
evaluation should be made. A score of ≤6 indicates severe
olfactory dysfunction including anosmia (Hummel et al.
2007).
DNA extraction
Genomic DNA was extracted from blood leukocytes
according to standard procedures.
Mutation detection methods
 Usher APEX microarray. DNA samples were analyzed
by Asper Biotech (Tartu, Estonia) for the presence
of known nucleotide substitutions and small deletions/
insertions in USH genes using the Usher APEX
microarray as described previously (Cremers et al.
2007). Two different versions of APEX were used;
version 5 (containing probes for 429 different USH
mutations) and version 6 (containing probes for 612
different USH mutations).
 Screening of selected single genes. Coding sequences
and flanking intronic sequences of USH1C, USH2A,
and CLRN1 were analyzed by Sanger sequencing, as
described previously (Dreyer et al. 2000, 2008; Roux
et al. 2006; Tranebjærg et al. 2011).
 Targeted NGS of Usher genes. DNA samples were ana-
lyzed using a customized NGS oligonucleotide-based
Cohort 1
26
Cohort 1a
(APEX/single gene 
sequencing)
9
Cohort 1b
(NGS panel
of USH genes)
17
USH1:11
USH2:14
USH3:1
USH1:2 USH2:7 USH1:10 USH2:6 USH3:1
Predicted
pathogenic
2
Predicted
pathogenic
7
Predicted
pathogenic
6
Predicted
pathogenic
5
USH1C: 1
2 mut: 1
CLRN1: 1
2 mut: 1
USH2A: 7
1 mut: 2
2 mut: 5
MYO7A: 5
2 mut: 5
CDH23: 1
2 mut: 1
USH2A: 5
2 mut: 5
Figure 1. Flow diagram of the mutation screening of cohort 1. The figure shows an overview of the total number of individuals in the cohort 1,
which is divided to subcohort 1a and subcohort 1b. Cohort 1 consists of all individuals investigated in this study. Cohort 1a consists individuals
investigated by other methods before Next Generation Sequencing (NGS) became available, and cohort 1b consists of individuals analyzed by
targeted NGS of known USH genes. Mut = mutation(s).
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target capture USH-panel (Otogenetics Corporation,
Norcross, GA). The USH panel included coding regions
and flanking intronic sequences of nine known genes
for USH: MYO7A, PCDH15, CDH23, USH1C, USH1G,
USH2A, ADGRV1, DFNB31, CLRN1, and the modifier
gene PDZD7. Sequencing was carried out using 100 bp
paired-end reads on an Illumina Hiseq2000 sequencer
with minimum guaranteed on-target average coverage
of 50–100X. The actual average coverage was very high
(450X). Two exons were not covered by NGS; USH2A
exon 1 (133 bp) and maximum 72 bp out of 617 bp of
DFNB31 exon 9. These two exons were Sanger
sequenced. Initial bioinformatics mapping to reference
sequence, variant calling and filtering was performed by
Otogenetics Corporation, delivered through http://
www.dnanexus.com together with a mutation report.
Databases, Alamut (Interactive Biosoftware v2.4) and
HGMDprof (http://www.biobase-international.com/
product/hgmd) were used to classify and annotate the
identified variants. Potentially pathogenic variants were
verified by Sanger sequencing. Primers used for verifica-
tion of identified variants are listed along with PCR
conditions in Table S4. Primer sequences used for
sequencing of uncovered exons are available upon
request. We were able to detect homozygous deletions
or duplications with the NGS panel data, but have not
performed copy number analysis for detection of
heterozygous deletions/duplications.
 USH2A Individuals with USH2 and no or only one
identified mutation were analyzed for the pathogenic
intronic variant c.7595-2144A>G in USH2A (Vache
et al. 2012) by Sanger sequencing. Primers used for
PCR amplification are listed along with PCR condi-
tions in Table S4.
Accession numbers
Nomenclature of mutations is according to HGVS
(www.hgvs.org) and based on the following accession num-
bers; NM_000260.3 (MYO7A), NM_033056.3 (PCDH15),
NM_022124.5 (CDH23), NM_005709.3 (USH1C), NM_
173477.4 (USH1G), NM_206933.2 (USH2A), NM_032
119.3 (ADGRV1), NM_015404.3 (DFNB31), NM_174878.2
(CLRN1), and NM_001195263.1 (PDZD7).
Results
Pathogenic variants identified in 21
unrelated USH individuals (cohort 1)
We identified pathogenic variants in 21 out of 26 unre-
lated individuals affected with USH; cohort 1 (Fig. 1;
Table 1).
Subcohort 1a: In the period of 2007–2009, before
NGS became available, mutations in DNA samples from
nine of these individuals (USH1 [n = 2], USH2
[n = 7]) were identified using a combination of Asper
APEX microarray for identification of previously
reported USH mutations and Sanger sequencing of
USH2A, USH1C and CLRN1. USH2A mutations were
identified in the seven persons with USH2. Further-
more, for one person with USH1, mutations were iden-
tified in USH1C (USH1-13). In another person
clinically diagnosed with USH1, mutations were identi-
fied in CLRN1 (USH3-1). We identified two mutations
in seven patients (1 USH1, 5 USH2, 1 USH3) and
one mutation in two patients (2 USH2; Table 1;
Tables S1–S3).
Subcohort 1b: The remaining 17 individuals were ana-
lyzed for mutations by targeted NGS of the genes known
to be associated with USH. Two mutations were identi-
fied in twelve individuals (USH1 [n = 7], USH2 [n = 4]
and USH3 [n = 1]). MYO7A mutations were identified in
five USH1 persons, CDH23 mutations in two USH1 indi-
viduals, and USH2A mutations in five USH2 persons. The
person clinically diagnosed with USH3 turned out to have
mutations in USH2A (USH2-20). In 5 individuals (3
USH1 and 2 USH2) no pathogenic variants were identi-
fied (Fig. 1).
Vache et al. (2012) reported the intronic pathogenic
variant c.7595-2144A>G in USH2A, resulting in the inser-
tion of a pseudoexon. This variant is located deep into
the intronic sequence and would therefore not be identi-
fied by either traditional USH2A screening or targeted
NGS. We decided to investigate the remaining USH2
individuals, with no or only one identified mutation in
USH2A, for this variant (e.g. USH2-21, USH2-29, USH2-
74 and USH2-77). However, none of these cases harbored
this variant.
In total, two mutations were detected in 19 of the
unrelated individuals in cohort 1, and only one muta-
tion was detected in two unrelated individuals; in total,
19 different mutations were detected. The identified
mutations and the method used are listed in Table 1.
Five novel mutations were identified: c.6517G>T,
p.(Glu2173*) and c.3862C>T, p.(Gln1288*) both in
CDH23 (USH1-6; USH-1-36), c.1146dupA, p.(Gln383fs*6)
in USH1C (USH1-13), c.1647T>G, p.(Cys549Trp) in
USH2A (USH2-34) and the splice mutation, c.254-1G>A
in CLRN1 (USH3-1). Only the c.6517G>T, p.(Glu2173*)
mutation in CDH23 was identified previously and reported
in the ExAC database with a frequency of 0.0017%. The
other four mutations were not observed in approximately
6500 individuals of European and African American
ancestry in the NHLBI Exome Sequencing Project nor in
the ExAC database or in Whole-exome sequencing of 2000
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Danish individuals (Lohmueller et al. 2013). No patients
with possible digenic inheritance of USH were identified
in cohort 1a.
Overview of mutations identified in the
Danish USH population
To obtain an overall picture of molecular findings in
patients with USH registered at the Danish National
Eye Clinic for the Visually Impaired, we pooled the
mutation data obtained from cohort 1 (21 unrelated
cases) with all previously published mutation data from
Danish USH patients (79 unrelated cases; Janecke et al.
1999; Dreyer et al. 2000, 2008; Cremers et al. 2007;
Tranebjærg et al. 2011; Dad et al. 2015). In total, we
collected mutation data from 100 USH probands.
Table 2 lists all mutations identified in the whole
cohort.
Mutations in patients with USH1
In the combined Danish cohort, one or two mutations were
identified in 32 USH1 families (36 individuals; Table 2;
Table S1). Mutations were identified in MYO7A in 75%
(24/32), in CDH23 in 16% (5/32), and in USH1C in 9% (3/
32) of the families. No mutation was identified in either
PCDH15 or USH1G. Two mutations were identified in 26
persons and one mutation in six.
Nonsense and missense mutations were observed most
frequently. Splice site mutations were only identified in
MYO7A and CDH23. The majority of the mutations only
appeared in a single patient (in heterozygous or homozy-
gous state). In contrast, the MYO7A mutation p.Cys31*
had an allele frequency of 45% (19 out of 42 MYO7A
alleles with identified mutation), and accounted for 33%
of all pathogenic USH1 alleles (19/58). The c.238dup
mutation in USH1C appeared in two patients.
Table 1. Mutations identified in 21 unrelated individuals (cohort 1).
Patient Gene Allele 1
Allele 1
Predicted protein Exon Allele 2
Allele 2
Predicted protein Exon Method
USH1-2 MYO7A c.93C>A p.(Cys31*) 3 c.93C>A p.(Cys31*) 3 A
USH1-31 MY07A c.93C>A p.(Cys31*) 3 c.93C>A p.(Cys31*) 3 A
USH1-1 MYO7A c.805_807del p.(Lys269del) 8 c.93C>A p.(Cys31*) 3 A
USH1-30 MYO7A c.1708C>T p.(Arg570*) 15 c.1708C>T p.(Arg570*) 15 A
USH1-3 MYO7A c.3503G>A p.(Arg1168Gln) 27a c.93C>A p.(Cys31*) 3 A
USH1-36 CDH23 c.3862C>T p.(Gln1288*) 32a c.3862C>T p.(Gln1288*) 32a A
USH1-6 CDH23 c.6517G>T p.(Glu2173*) 48 c.6517G>T p.(Glu2173*) 48 A
USH1-6B CDH23 c.6517G>T p.(Glu2173*) 48 c.6517G>T p.(Glu2173*) 48
USH1-13 USH1C c.1146dupA p.(Gln383Thrfs*6) 14 c.1146dupA p.(Gln383Thrfs*6) 14 C
USH2-1 USH2A c.1606T>C p.(Cys536Arg) 9 c.1606T>C p.(Cys536Arg) 9 A
USH2-34 USH2A c.1647T>G p.(Cys549Trp) 6 c.7524delT p.(Arg2509Glyfs*19) 40 D
USH2-3 USH2A c.2299delG p.(Glu767Serfs*21) 13 c.2299delG p.(Glu767Serfs*21) 13 A
USH2-11 USH2A c.2299delG p.(Glu767Serfs*21) 13 c.4106C>T p.(Ser1369Leu) 19 B
USH2-17 USH2A c.2299delG p.(Glu767Serfs*21) 13 c.2299delG p.(Glu767Serfs*21) 13 B
USH2-21 USH2A c.2299delG p.(Glu767Serfs*21) 13 NI NI D
USH2-59 USH2A c.2299delG p.(Glu767Serfs*21) 13 c.2299delG p.(Glu767Serfs*21) 13
USH2-52 USH2A c.2299delG p.(Glu767Serfs*21) 13 c.3407G>A p.(Ser1136Asn) 17 D
USH2-52a USH2A c.2299delG p.(Glu767Serfs*21) c.3407G>A p.(Ser1136Asn)
USH2-29 USH2A c.2522C>A p.(Ser841Tyr) 13 NI NI B
USH2-2 USH2A c.9370A>G) p.(Arg3124Gly) 47 c.2299delG p.(Glu767Serfs*21) 13 A
USH2-9 USH2A c.10561T>C p.(Trp3521Arg) 53 c.486-14G>A p.(?) Intron 2 A
USH201 USH2A c.14384T>G p.(Leu4795Arg) 66 c.2299delG p.(Glu767Serfs*21) 13 A
USH3-12 CLRN1 c.254-1G>A
(IVS11G>A)
p.(?) 1 c.254-1G>A
(IVS11G>A)
p.(?) 1 E
NI, not identified.
Mutations identified in 21 unrelated individuals (and family members) from a cohort of 26 individuals with USH using different methods. A: tar-
geted NGS of USH genes, B: APEX microarray (Dreyer et al. 2008). C: USH1C Sanger sequencing (Dad et al. 2015). D: USH2A Sanger sequencing
(Janecke et al. 1999; Dreyer et al. 2000). E: CLRN1 Sanger sequencing (Cremers et al. 2007).
Mutations in bold are novel according to HGMDprof and LOVD USH databases 081015.
1Initially diagnosed as USH3.
2Initially diagnosed as USH1. Nomenclature of mutations is based on the following accession numbers; NM_000260.3 (MYO7A), NM_022124.5
(CDH23), NM_005709.3 (USH1C), NM_206933.2 (USH2A) and NM_174878.2 (CLRN1). Nomenclature is according to HGVS (www.hgvs.org).
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Table 2. Mutations identified in 100 individuals with USH from Denmark.
Gene Mutation Predicted protein Exon Alleles Classification
MYO7A
Nonsense mutations c.93C>A p.(Cys31*) 3 19 Pathogenic
c.1708C>T p.(Arg570*) 15 2 Pathogenic
c.1996C>T p.(Arg666*) 17 1 Pathogenic
c.2055C>A p.(Tyr685*) 17 1 Pathogenic
c.5215C>T p.(Arg1739*) 38 1 Pathogenic
c.5392C>T p.(Gln1798*) 39 1 Pathogenic
c.5824G>T p.(Gly1942*) 42 1 Pathogenic
Missense mutations c.634C>T p.(Arg212Cys) 7 2 Pathogenic
c.905G>A p.(Arg302His) 9 1 UV2
c.3503G>A p.(Arg1168Gln) 27a 1 UV3
c.3719G>A p.(Arg1240Gln) 29 3 Pathogenic
c.3862G>C p.(Ala1288Pro) 30 1 UV3
c.4882G>T p.(Ala1628Ser) 36 3 UV2
Deletions/duplications/
insertions
c.805_807delAAG p.(Lys269del) 8 1 UV3
c.3040_3043delins
TACTTCCAGGGGACA
p.(Thr1014Tyrfs*52) 24 2 Pathogenic
c.6025delG p.(Ala2009Profs*32) 44 1 Pathogenic
Splice site mutations c.1555-8C>G (IVS13-8C>G) p.(?) 13 1 UV4
CDH23
Nonsense mutations c.3862C>T p.(Gln1288*) 32a 2 Pathogenic
c.6517G>T p.(Glu2173*) 48 2 Pathogenic
Splice site mutations c.4489-2A>C p.(?) 35 2 Pathogenic
c.6050-9G>A p.(?) 45 2 Pathogenic
c.7872G>A p.(Glu2624Glu)/p.(?) 54 2 UV4
USH1C
Nonsense mutations c.91C>A p.(Arg31*) 2 1 Pathogenic
Deletions/duplications/
insertions
c.238dup p.(Arg80Profs*69) 3 3 Pathogenic
c.1146dup p.(Gln383fs*6) 14 2 Pathogenic
USH2A
Nonsense mutations c.187C>T p.(Arg63*) 2 1 Pathogenic
c.1876C>T p.(Arg626*) 11 2 Pathogenic
c.2023C>T p.(Gln675*) 12 3 Pathogenic
c.2028C>A p.(Cys676*) 12 1 Pathogenic
c.2797C>T p.(Gln933*) 13 2 Pathogenic
c.3309C>A p.(Tyr1103*) 16 1 Pathogenic
c.4957C>T p.(Arg1653*) 24 1 Pathogenic
c.5473G>T p.(Glu1825*) 27 1 Pathogenic
c.5653A>T p.(Arg1885*) 28 1 Pathogenic
c.9120G>A p.(Trp3040*) 46 3 Pathogenic
c.10684G>T p.(Glu3562*) 54 2 Pathogenic
c.11416G>T p.(Glu3806*) 59 1 Pathogenic
c.11864G>A p.(Trp3955*) 59 3 Pathogenic
Missense mutations c.488G>A p.(Cys163Tyr) 3 1 UV2
c.949C>A p.(Arg317Arg) 6 1 UV4
c.1000C>T p.(Arg334Trp) 6 1 Pathogenic
c.1036A>C p.(Asn346His) 6 1 Pathogenic
c.1606T>C p.(Cys536Arg) 9 4 Pathogenic
c.1647T>G p.(Cys549Trp) 10 1 UV3
c.2137G>C p.(Gly713Arg) 12 1 UV2
c.2276G>T p.(Cys759Phe) 13 2 Pathogenic
c.2522C>A p.(Ser841Tyr) 13 1 UV1
c.3407G>A p.(Ser1136Asn) 17 1 UV3
c.3635C>T p.(Pro1212Leu) 17 1 UV3
c.4106C>T p.(Ser1369Leu) 19 1 UV3
(Continued)
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The pathogenic variants in the CDH23 gene; c.3862C>T,
p.(Gln1288*), c.4489-2A>C, c.6050-9G>A and c.7872G>A,
p.(Glu2624Glu), were identified in individuals of Iraqi, Sri
Lankan or Pakistani origin (Table S1). Only the mutation
c.6517G>T, p.(Glu2173*) was identified in a person with
Danish origin (USH1-6). Two nonsense mutations
p.(Gln1288*) and p.(Glu2173*) were identified. The addi-
tional three mutations all affect the splicing of the CDH23
transcript, including the “silent” mutation c.7872G>A,
p.(Glu2624Glu) located at the last basepair in exon 54.
This mutation is assumed to activate a cryptic splice site
in intron 54, leading to extension of exon 54 with 86
nucleotides and resulting in a frame shift (Vache et al.
2012).
While the majority of pathogenic variants in MYO7A
were identified in individuals with Danish origin,
only two pathogenic variants, c.3040_3043delin-
sTACTTCCAGGGGACA and c.1708C>T, were identified
in individuals of Turkish and Sri Lankan origin,
respectively.
Mutations in patients with USH2
In the combined Danish cohort, 67 unrelated USH2 fami-
lies (81 individuals) harbored mutations in one or both
alleles, all affecting USH2A (Table 2; Table S2). Two
patients (USH2-13 and USH-60) had actually three muta-
tions in total, two on the same allele (Table S2). In this
study, the splice variant, c.486-14G>A in intron 2 in
USH2A, was identified in trans with a missense mutation
c.10561T>C, p.(Trp3521Arg) in exon 53. In Le Guedard-
Mereuze et al. (2010), c.486-14G>A was investigated in a
splicing reporter minigene assay and was shown to result in
creation of a new 30AG acceptor splice site and as a result
of this inclusion of intronic sequence in the open reading
frame leading to a missense mutation (p.Met162Ile) and
addition of 4 additional residues (between codon 162 and
163) and the authors speculate that the change will alter
the structure of the USH2A protein. The ExAC database
report that c.486-14G>A is only observed in 2 of 120994
alleles consistent with the frequency of Usher syndrome.
Table 2. Continued.
Gene Mutation Predicted protein Exon Alleles Classification
c.5270A>G p.(Tyr1757Cys) 26 1 UV2
c.9370A>G p.(Arg3124Gly) 47 2 UV3
c.10510C>A p.(Pro3504Thr) 53 2 UV3
c.10561T>C p.(Trp3521Arg) 53 4 UV3
c.12161G>T p.(Ser4054Ile) 62 2 UV3
c.13316C>T p.(Thr4439Ile) 63 3 UV3
c.13776G>C p.(Gln4592His) 63 1 UV3
c.14384T>G p.(Leu4795Arg) 66 2 UV3
Deletions/duplications/
insertions
c.672_1840+1160del p.(Ser224Argfs*5) 4-10 2 Pathogenic
c.920_923dup p.(His308Glnfs*16) 6 5 Pathogenic
c.1965delT p.(Cys655Trpfs*101) 11 1 Pathogenic
c.2299delG p.(Glu767Serfs*21) 13 56 Pathogenic
c.2878_2879delAA p.(Asn960Serfs*4) 14 2 Pathogenic
c.4628_4987del p.(Gly1543_Pro1662del) 22-24 1 Pathogenic
c.6795_6797delATA p.(Glu2265_Tyr2266
delinsAsp)
35 1 UV3
c.7195_7207del p.(Ile2399Phefs*10) 38 1 Pathogenic
c.7524delT p.(Arg2509Glyfs*19) 40 1 Pathogenic
c.9770dup p.(Asn3257Lysfs*9) 50 1 Pathogenic
c.10345delinsAA p.(Glu3449Lysfs*25) 52 1 Pathogenic
Splice site mutations c.486-14G>A p.(?) Intron 2 1 UV4
CLRN1
Splice site mutations c.254-1G>A p.(?) 2 Pathogenic
Mutations identified in 100 individuals with USH from Denmark. The pathogenity is defined according to LOVD Usher database. Classification:
Neutral – UV1 (certainly neutral) – UV2 (likely neutral) – UV3 (likely pathogenic) – UV4 (certainly pathogenic) – Pathogenic. Novel nonsense and
splice site mutations were classified as pathogenic and prediction of the pathogenity of the novel missense mutations were performed in silico,
using the web tools SIFT, Mutation taster, Polyphen 2 and Align GVGD. Nomenclature of mutations is based on the following accession numbers;
NM_000260.3 (MYO7A), NM_022124.5 (CDH23), NM_005709.3 (USH1C), NM_206933.2 (USH2A) and NM_174878.2 (CLRN1). Nomenclature is
according to HGVS (www.hgvs.org).
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The most frequent USH2 mutation was the c.2299delG
mutation, which was identified in 56 alleles (45% of a
total of 125 USH2A alleles with identified mutations).
The mutation c.920_923dup was detected in five alleles
(4%, 5/125). The mutations c.10561T>C, p.(Trp3521Arg)
and c.1606T>C, p.(Cys536Arg) were identified in four
alleles (3%, 4/125) each, and the four mutations
c.2023C>T, p.(Gln675*), c.9120G>A, (p.(Trp3040*),
c.11864G>A, p.(Trp3955*), and c.13316C>T, p.(Thr
4439Ile) in three alleles each (2%). The rest of the muta-
tions were identified only in one or two alleles each. All
individuals were of Danish origin.
Mutation in a patient with USH3
In the combined Danish cohort, only one USH3 individ-
ual, the above described USH3-1 (Table 1), was geno-
typed (homozygous for the mutation c.254-1G>A in
CLRN1). Her parents were consanguineous and of Syrian
origin (Table 2; Table S3). The consequence of the c.254-
1G>A mutation is likely a skipping of exon 2, as it affects
a splice site.
Molecular findings, in total
Full or partial molecular genetic diagnosis was obtained
in 118 patients with USH, representing 100 probands and
18 affected family members. From the total cohort of 100
probands two or three mutations have so far been identi-
fied in 26 USH1, 58 USH2, and 1 USH3 individuals and
one mutation has been identified in 6 individuals with
USH1 and 9 individuals with USH2 (Tables S1–S3).
Clinical findings
Our entire cohort of 107 individuals (30 USH1, 76 USH2
and one USH3), were between 6 and 93 years of age (av-
erage age 49.9 years, median 51 years). All patients ful-
filled the criteria for RP, nyctalopia, visual field
constriction, retinal arteriolar attenuation, retinal pigmen-
tation presenting as bone spicules, optic disc pallor, as
well as severely reduced or flat standard full-field ERG.
The slit-lamp examination showed cataract in 71% of the
examined individuals; 18/30 of the persons with USH1
and 57/76 of the persons with USH2. The single USH3
individual did not have cataract at the age of 17. The 75
individuals with cataract were between 21 and 93 years of
age with an average age of 55.7 years (median 54 years).
The 32 individuals without cataract were between 6 and
93 years of age and the average age was 26.5 years
(median 32 years).
Forty-four individuals (14 USH1, 29 USH2 and one
USH3) were examined by OCT, these individuals were
between 6 and 93 years old with an average age of 38.8
(median 39.5). This examination revealed cystic macular
edema in 52%: 8/14 USH1, 14/29 USH2, and in the single
USH3 case (Tables S1–S3). The 23 individuals with macu-
lar edema were between 11 and 77 years old and the aver-
age age was 38 years (median 40 years). The 21
individuals with no macular edema were between 6 and
65 years of age (average 36 years; median 39 years). In
our cohort there was no case with cystic macular edema
led to macular atrophy or macular hole.
The olfactory function in all twelve examined individu-
als (2 USH1, 10 USH2) were within normal range in all.
All had a score of 11 or 12 out of 12 possible.
Discussion
The simultaneous investigation of all known USH genes
by NGS technology is likely to facilitate the molecular
diagnosis and broaden our view on the clinical features of
the USH syndromes. However, even targeted NGS of all
known USH genes does not lead to a molecular diagnosis
in all cases. In subcohort 1b, two pathogenic variants
were identified in 12 of 17 individuals (71%). Similar
studies have achieved a similar percentage. Bonnet et al.
(2011) identified two pathogenic variants in 41 of 54
USH patients (76%) and one mutation in 8 additional, in
total they found mutations on 83% of the alleles (Bonnet
et al. 2011). Le Quesne Stabej et al., identified two patho-
genic variant in 112 of 172 USH patients (65%) and one
in 27 USH patients (Le Quesne et al. 2012). In total they
found mutations on 73% of the alleles. The reasons for
absence of identification of two mutations in about 35–
24% of the investigated patients in these studies may be
either misdiagnosis, the presence of pathogenic variants
outside the coding regions of the genes tested, or in genes
not yet associated with USH. The recently identified USH
genes, CIB2, HARS and ABHD12 were not investigated, as
they were not associated with USH, when the studies were
initiated. However, mutations in these genes are probably
very rare causes of USH (Jan 2013).
Furthermore, the clinical diagnosis of USH can be chal-
lenging. The various USH phenotypes may resemble other
deaf-blindness syndromes, the association between deaf-
ness and RP might be caused by unrelated genetic events,
or the USH case may be atypical. Mutations in several
genes may result in either USH or congenital deafness.
In most USH cases the differential diagnosis is easy
mainly due to the degree of hearing impairment as shown
by the audiogram. In a few patients, however, the clinical
diagnosis may be ambiguous. In this study, the involved
gene deviated in two patients. In cohort 1a, one person
(USH3-1), initially diagnosed with USH1, was found to
be homozygous for the c.254-1G>A mutation in the
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USH3 gene CLRN1. This patient did in fact present a
phenotype, which differed from the typical USH3 pheno-
type, showing profound congenital hearing impairment
and early onset of RP. However, she had progressive hear-
ing impairment which is characteristic of USH3 and the
underlying medical information from her early years was
very sparse. Another person (USH2-20), initially thought
to have USH3, was found to have an USH2A genotype;
c.[14384T>G(;)2299delG]. A reassessment of the clinical
data made clear that USH2-20 actually presented an unu-
sual clinical picture with recognition of hearing impair-
ment and RP after the age of 40. Thus, the specialized
ophthalmological examinations should always be accom-
panied by molecular genetic examinations.
In the combined Danish USH cohort a total of 100
unrelated individuals have been genotyped. Two muta-
tions were identified in 85 and only one mutation was
found in the 15 remaining. As mutation screening was
performed by screening of single genes or testing for
known mutations (APEX) it is possible that the disease
causing mutations in these 15 patients are present in
other USH genes not screened, and the identified muta-
tions only are coincidental findings. In the Danish USH1
cohort mutations in CDH23 were mainly identified in
individuals of non-Danish origin, whereas mutations in
MYO7A, mostly were identified in individuals with Dan-
ish origin. Compared to the mutation pattern obtained in
USH1 cohorts from other countries, MYO7A mutations
accounted for a larger fraction of the mutations in the
Danish cohort. In cohorts from Britain, France and Italy,
61–63.3% of the genotyped individuals with USH1 had
mutations in MYO7A (Roux et al. 2011; Le Quesne et al.
2012). The mutation, c.93C>A (p.Cys31*) in MYO7A,
accounts for 33% of all USH1 alleles with identified
mutations in Denmark. Mutations were identified in
more than 100 individuals with USH1 from France, but
the p.Cys31* mutation was not identified in any of these
individuals (Roux et al. 2006, 2011; Bonnet et al. 2011).
Le Quesne et al. (2012) identified a single family with
p.Cys31* mutation in a cohort of 47 individuals with
USH1 from Britain. The high allele frequency of this
mutation among Danish individuals with USH1 suggests
that the p.Cys31* mutation is a Danish founder muta-
tion, in agreement with previous observations (Janecke
et al. 1999). The presence of the p.Cys31* mutation
might also explain the higher fraction of mutations in
MYO7A in Denmark compared with other countries.
The fraction of individuals with mutations in CDH23
and USH1C varied in different countries, from 13–20%
and 4.5–16%, respectively (Roux et al. 2011; Le Quesne
et al. 2012).
In the Danish cohort of individuals with USH2, muta-
tions were solely identified in USH2A, in agreement with
previous studies from several other countries, showing
that USH2A is the main contributor and DFNB31 and
ADGRV1 represents minor contributors (Garcia-Garcia
et al. 2011; Le Quesne et al. 2012). In the entire cohort of
100 individuals, mutations in CLRN1 were identified only
in one individual of non-Danish origin. Similarly, CLRN1
mutations are also rare in most other populations (Bon-
net et al. 2011; Le Quesne et al. 2012). The USH3 pheno-
type and especially molecularly verified cases are rare, as
many patients with a clinical diagnosis of USH3 in fact
turn out to have mutations in USH2 (Bonnet et al. 2011;
Le Quesne et al. 2012). Only in Finland and among
Ashkenazi Jews, the USH3 phenotype with mutations in
CLRN1 is frequent and accounts for 40% of all USH cases
(Joensuu et al. 2001; Ness et al. 2003; Vastinsalo et al.
2006; Herrera et al. 2008).
The mutation c.2299delG (p.Glu767Serfs*21) in
USH2A had an allele frequency of 45% in the Danish
USH2 cohort. Other studies also report that this muta-
tion is frequent, but the allele frequency varies. Le
Quesne et al. (2012) reported a c.2299delG allele fre-
quency of 33.7% in a cohort of 96 British USH2 indi-
viduals with identified mutations. In Spain, the allele
frequency of c.2299delG was only 15% (Garcia-Garcia
et al. 2011). The allele frequency thus varies from being
high in Northern Europe (45%) to being low in South-
ern Europe (15%). The higher frequency in Northern
Europe could indicate that the mutation arose many
generations back in a common ancestor from Scandi-
navia and from here spread to Southern Europe via
migration. Alternatively, as proposed by Dreyer et al.
(2001), “it is tempting to speculate that the c.2299delG
mutation results from an old mutational event that
happened to arise on the most common haplotype in
the present European genetic background and that was
spread, though migration and subsequent founder
effects, throughout Europe”.
The location of the affected residues in the predicted
structure of the proteins, are shown in Figure 2. In
MYO7A, affected residues were located in all domains
except in the coiled–coil domain. The motor domain was
the most frequently affected as also reported in other
studies (Petit 2001). This domain regulates ATP hydroly-
sis and interacts with actin filaments (Sata et al. 1997).
Previous studies have suggested that it affects protein
stability (Hasson et al. 1997) and motor function (Watan-
abe et al. 2008). In USH1C, only mutations affecting the
N-terminus, leading to truncation of the protein, were
identified. In CDH23, we only identified mutations affect-
ing residues located in the extracellular cadherin 1–2
domain, which plays a major role in the function of the
protein and which also interacts with PCDH15. This
interaction is critical for sound detection via mechano-
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transduction by the sensory hair cells. The majority of the
USH2A mutations affect residues located in the laminin
EGF-like domains and in the FN3 domains. Laminin
EGF-like domains are thought to play a role in the fold-
ing of the protein, as mutations in this module result in
abnormal USH2A proteins (Dreyer et al. 2000). FN3
domains are found in extracellular proteins, and play a
role in the spatial arrangement of other domains and in
the formation of protein–protein interfaces.
Seventy-one percent of the examined patients had cat-
aract and 52% had macular edema. This underscores the
importance of longitudinal ophthalmological monitoring
for possible therapeutic action to preserve central vision
as long as possible.
We only had opportunity to examine the olfactory
function in a very few individuals, mainly individuals
with USH2. This is partly due to the difficult communi-
cation, which requires the assistance of personnel skilled
in nonverbal communication. The results of our examina-
tion should therefore only be considered as a pilot test.
Data regarding the association of USH with olfactory dys-
function are conflicting. Zrada et al., identified olfactory
dysfunction in 11 out of 22 individuals with USH (5
USH1 and 6 USH2) by the University of Pennesylvania
Smell Identification Test (UPSIT; Zrada et al. 1996),
while Seeliger et al., could not identify any olfactory dys-
function in their cohort of 39 persons with USH (8
USH1, 31 USH2; Seeliger et al. 1999). However, the
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Figure 2. Predicted structures of the affected proteins. Location of affected residues in 100 Danish USH individuals, are indicated. Myosin VIIa
contains eight functional domains; the motor domain, the IQ motif containing five leucine-glutamine repeats, the coiled–coil (CCl) domain, two
MyTH4 repeats separated by the src homology-3 (SH3) domain and a FERM domain. The harmonin transcripts can be divided into three isoforms,
which differ in the composition of the C-terminal part of the protein. The largest isoform (b) contains three PDZ domains, two coiled–coil
domains and a PST domain, the shortest isoform (c) contains two PDZ domains and one coiled–coil domain. Cadherin-23 contains three domains,
an extracellular cadherin 1–27 domain, a helical transmembrane domain and a cytoplasmic domain. Usherin contains ten different domains: one
laminin G-like domain, one laminin N-terminal domain, ten laminin-type EGF-like domains, 35 fibronectin type III domains (FN3), one
transmembrane domain (TM), one PDZ domain and one cysteine-rich domain. Mutations in blue are nonsense mutations, mutations in black are
missense mutations and mutations in red are frameshift mutations.
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majority of USH proteins are expressed in olfactory cells
(Wolfrum et al. 1998). Recently the USH proteins
encoded by MYO7A, USH1C; USH1D, USH1F, USH1G,
USH2A, USH2C and USH2D were shown to be expressed
in the murine olfactory epithelium (OE). Furthermore,
investigation of five murine models with mutations in
MYO7A, USH1C, CDH23, PCDH15 and USH1G, respec-
tively, showed that mutations in USH1C and USH1G lead
to olfactory impairment in the mouse (Jansen et al.
2016). Thus, it is not unlikely that olfactory function
might be impaired in some USH individuals.
Targeted NGS of USH combined with analysis for large
genomic rearrangements has improved molecular genetic
diagnosis in USH. An early genetic diagnosis is essential
for the patient regarding the possibilities of cochlear
implant, genetic counseling, and future advanced
treatments.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Mutations and clinical information of Danish
individuals with USH1. NI: not identified; NA: Informa-
tion not available; : absent, +: present; HI: hearing
impairment; Seq: sequencing, APEX: arrayed primer
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extension microarray; mutations in bold: novel accord-
ing to HGMDprof and LOVD USH database 161015;
Accession numbers: MYO7A (NM_000260.3); CDH23
(NM_022124.5); USH1C (NM_005709.3). Gray-marked
individuals indicate a family member. Information about
onset of night blindness is in several cases based on infor-
mation obtained from the patient. It was often difficult
for the patient to set the exact age at onset, and may thus
be associated with inaccuracy.
Table S2. Mutations and clinical information of Danish
individuals with USH2. All mutations are identified in
USH2A and in patients with Danish origin. NI: not iden-
tified; NA: information not available; : absent, +: pre-
sent; HI: hearing impairment; Seq: sequencing, APEX:
arrayed primer extension microarray; mutations in
bold: novel according to HGMDprof and LOVD USH
database 161015; Accession number: USH2A
(NM_206933.2). Gray-marked individuals indicate a fam-
ily member. Information about onset of night blindness is
en several cases based on information obtained from the
patient. In several cases it was difficult for the patient to
set the exact age at onset, and may thus be associated
with inaccuracy.
Table S3. Clinical data and mutations identified in an
individual with USH3. : absent, +: present; mutations in
bold: novel according to HGMDprof and LOVD USH
database 161015; Accession number: CLRN1
(NM_174878.2).
Table S4. Primer list and PCR program. Table includes
all primers used for verification of the variants identified
by NGS and primers for Sanger sequencing of the intro-
nic variant c.7595-2144A>G in USH2A.
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